Movement Alert｜United Therapeutics Falls 5.19% in Regular Trading, Trading at $542.915

Market Focus

Oct 03

On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.

Within the Biotechnology sector where United Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Insmed up 1.36%, AbbVie up 0.89%, Natera down 0.22%, Moderna down 0.42%, Amgen down 0.71%.

United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company offers Tyvaso DPI, Tyvaso inhalation solution, Remodulin injection, Orenitram, and Adcirca for pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. It is also developing ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1110967922"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110967922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110967922?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-03 02:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110967922","market":"hk","top_or_hot":-1,"title":"Movement Alert｜United Therapeutics Falls 5.19% in Regular Trading, Trading at $542.915","media":"Market Focus","content":"<p><p>On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.</p><p>Within the Biotechnology sector where United Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Insmed up 1.36%, AbbVie up 0.89%, Natera down 0.22%, Moderna down 0.42%, Amgen down 0.71%.</p><p>United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company offers Tyvaso DPI, Tyvaso inhalation solution, Remodulin injection, Orenitram, and Adcirca for pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. It is also developing ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜United Therapeutics Falls 5.19% in Regular Trading, Trading at $542.915</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜United Therapeutics Falls 5.19% in Regular Trading, Trading at $542.915\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-03 02:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.</p><p>Within the Biotechnology sector where United Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Insmed up 1.36%, AbbVie up 0.89%, Natera down 0.22%, Moderna down 0.42%, Amgen down 0.71%.</p><p>United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company offers Tyvaso DPI, Tyvaso inhalation solution, Remodulin injection, Orenitram, and Adcirca for pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. It is also developing ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"UTHR","symbol_name":"美国联合医疗","start_time":0,"source_url":"","article_id":"1110967922","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110967922","pubTimestamp":1790965936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.Within the Biotechnology sector where United Therapeutics belongs,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"UTHR":"美国联合医疗"},"translate_title":"走势警报|United Therapeutics 常规交易下跌 5.19%，交易价格为 542.915 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1},"content_text":"On October 2, United Therapeutics fell 5.19% in regular trading, trading at $542.915 USD/share, with Turnover of $295 million.Within the Biotechnology sector where United Therapeutics belongs, individual stock performance was mixed. Among individual stocks, Insmed up 1.36%, AbbVie up 0.89%, Natera down 0.22%, Moderna down 0.42%, Amgen down 0.71%.United Therapeutics Corporation is a biotechnology company that engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases. The company offers Tyvaso DPI, Tyvaso inhalation solution, Remodulin injection, Orenitram, and Adcirca for pulmonary arterial hypertension, as well as Unituxin for high-risk neuroblastoma. It is also developing ralinepag for PAH and nebulized Tyvaso for idiopathic pulmonary fibrosis.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}